



Bio-Quick Corporation

Contact: Wei-Sing Chu  
Location: Silver Spring, USA  
Email: wchu@bio-quick.com  
Tel: 301.675.8666



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

## Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** Bio-Quick Corporation is a start-up company developing pathology instruments and assays based in Silver Spring, Maryland. Bio-Quick's R&D and business activities aim at significantly improving the speed, cost-effectiveness, and efficiency of pathological research and cancer diagnosis.

**Target Market(s):** hospitals and medical research institutions world wide

## Key Value Drivers

**Technology\*:** Bio-Quick's proprietary technologies include the ultrasound-facilitated tissue preservation technology (US-FFPE), apparatus and methods for efficient processing of biological samples on slides, and devices and methods for on-slide biomolecule extraction. These innovative technologies, invented by Dr. Wei-Sing Chu, founder of Bio-Quick, have been patented, and Bio-Quick has exclusive license for the rights to commercialize these technologies.

**Competitive Advantage:** The US-FFPE technology can significantly reduce the time needed for the current FFPE protocol from 1-to-2 days down to less than 1 hour. This approach not only maintains the "gold standard" FFPE morphology, but also allows automation and standardization for the tissue fixation and process. In addition, the US-FFPE technology permits precise controls in the biomolecular modification and cross-linking in formalin fixation, so that tissue specimens are "frozen in time" at the point of formalin fixation, preserving the integrity of biomolecules as well as morphological features. This technology has a great potential to minimize pre-analytical variables for downstream assays.

**Plan & Strategy:** seeking a strategic partner

\*Technology funded by the *National Cancer Institute* and being commercialized under the NIH-CAP

## Management

### Leadership:

Wei-Sing Chu, President and CEO  
Andrew Ji, Vice President, Business Development  
Feng Tao, Chief Operating Officer  
Nianxiang (Nick) Zou, Vice President, IP and R&D

### Scientific Advisory Board:

## Product Pipeline

<b>Developmental Stage</b>	US-FFPE prototype	Enhanced US-FFPE prototype	Automatic US-FFPE devices			
<b>Financial Source</b>	SBIR Phase I	SBIR Phase II	Private investment			
<b>Production (unit/year)</b>	1-5 investigational devices	20-50 optimized investigational devices	Up to 100 advanced Automatic devices			
<b>Marketing Strategy</b>	Independent	Independent	Partnership			
	2008	2009	2010	2011	2012	2013